Literature DB >> 18158960

Long-term outcome after bone marrow transplantation for aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning regimen.

Yoshihiro Inamoto1, Ritsuro Suzuki, Yachiyo Kuwatsuka, Takahiko Yasuda, Taro Takahashi, Akane Tsujimura, Kyoko Sugimoto, Taku Oba, Seitaro Terakura, Yoshiko Atsuta, Makoto Murata, Masafumi Ito, Yoshihisa Kodera, Koichi Miyamura.   

Abstract

We retrospectively studied 49 patients in a single institute to evaluate the long-term outcome of total lymphoid irradiation (TLI) conditioning for allogeneic stem cell transplantation (allo-SCT) to treat aplastic anemia (AA). Most of the patients had received transfusions and had undergone previous treatment, with 33 receiving related transplants and 16 receiving unrelated transplants. Conditioning consisted of cyclophosphamide (Cy; 200 mg/kg) plus TLI (750 cGy) for related transplantation and Cy plus total body irradiation (TBI; 500 cGy) and TLI (500 cGy) for unrelated transplantation. Antithymocyte globulin (ATG) was added for 6 of the unrelated transplantations. Graft-versus-host-disease (GVHD) prophylaxis consisted mainly of cyclosporine (CSA) and methotrexate (MTX). Graft failure developed in 2 patients (4.1%). With a median follow-up of 7 years, overall survival (OS) was 81% and was not statistically significantly different between the patients receiving related transplants and those receiving unrelated transplants. In multivariate analyses, a history of previous treatment with ATG was the sole factor associated with a worse survival rate, and the interval from diagnosis to treatment was not prognostic. The incidence of acute (grade II to IV) GVHD (aGVHD) was 23%, and that of chronic GVHD (cGVHD) was 29%. Female-to-male transplantation was the sole factor associated with chronic GVHD. B cell lymphoproliferative disorder developed only after the ATG-containing conditioning. No other secondary malignancies developed after long-term follow-up. Our findings suggest that TLI conditioning is feasible and effective for patients with AA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18158960     DOI: 10.1016/j.bbmt.2007.06.015

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  7 in total

1.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report.

Authors:  Lindsay M Morton; Wael Saber; K Scott Baker; A John Barrett; Smita Bhatia; Eric A Engels; Shahinaz M Gadalla; David E Kleiner; Steven Pavletic; Linda J Burns
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-12       Impact factor: 5.742

2.  Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia.

Authors:  Yoshihiro Inamoto; Mary E D Flowers; Tao Wang; Alvaro Urbano-Ispizua; Michael T Hemmer; Corey S Cutler; Daniel R Couriel; Amin M Alousi; Joseph H Antin; Robert Peter Gale; Vikas Gupta; Betty K Hamilton; Mohamed A Kharfan-Dabaja; David I Marks; Olle T H Ringdén; Gérard Socié; Melhem M Solh; Görgün Akpek; Mitchell S Cairo; Nelson J Chao; Robert J Hayashi; Taiga Nishihori; Ran Reshef; Ayman Saad; Ami Shah; Takanori Teshima; Martin S Tallman; Baldeep Wirk; Stephen R Spellman; Mukta Arora; Paul J Martin
Journal:  Biol Blood Marrow Transplant       Date:  2015-05-30       Impact factor: 5.742

3.  Favorable outcomes in patients surviving 5 or more years after allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

Authors:  Robert Quan Le; Margaret Bevans; Bipin N Savani; Sandra A Mitchell; Kate Stringaris; Eleftheria Koklanaris; A John Barrett
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-17       Impact factor: 5.742

4.  TLI in pediatric patients.

Authors:  A Ocanto; A Escribano; L Glaría; I Rodríguez; C Ferrer; C Huertas; A Pérez; R Morera
Journal:  Clin Transl Oncol       Date:  2019-09-21       Impact factor: 3.405

5.  Total lymphoid irradiation based conditioning for hematopoietic stem cell transplantation in severe aplastic anemia.

Authors:  Yun-Hee Lee; Ji-Yoon Kim; Byung-Ock Choi; Mi-Ryeong Ryu; Su-Mi Chung
Journal:  Radiat Oncol J       Date:  2012-12-31

Review 6.  Unrelated donor stem cell transplantation in acquired severe aplastic anemia: a systematic review.

Authors:  Frank Peinemann; Ulrich Grouven; Nicolaus Kröger; Max Pittler; Beate Zschorlich; Stefan Lange
Journal:  Haematologica       Date:  2009-07-31       Impact factor: 9.941

7.  TBI with lung dose reduction does not improve hematopoietic cell homing to BM during allogeneic transplantation.

Authors:  A K Singh; J Chen; R Calado; A Sowers; J B Mitchell; A J Barrett
Journal:  Bone Marrow Transplant       Date:  2009-06-15       Impact factor: 5.483

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.